Losartan Potassium raw material Losartan Potassium Powder

CAS:124750-99-8

MF: C22H23ClKN6O

MW:462.01

EINECS:200-287-4

Specification​: 99% min Losartan Potassium Powder

Sample:Losartan Potassium Powder

Packaging:1kg/bag, 25kg/drum

Brand: Henrikang

Appearance: White

Storage: Cool Dry Place

Shelf Life: 2 Years

Test Method: HPLC

Losartan Potassium Powder Usage and Synthesis.

Chlorosartan potassium is a new type of non-peptide angiotensin II receptor (AT1) antagonist, metabolised in vivo to produce EXP3174, which is more active and longer-lasting than the parent drug, and the half-life of Chlorosartan and EXP3174 is 2.2 hours and 6.7 hours respectively.

Potassium Chlorosartan has good anti-hypertensive effect and protection of heart, kidney and brain, reversal of myocardial and vascular wall hypertrophy, sodium excretion and diuresis as well as promotion of uric acid excretion and other effects. The incidence of adverse reactions is low and well tolerated by patients.

Uses and functions of Losartan Potassium.

Chlorosartan potassium is a medicine used in the treatment of essential hypertension in patients treated with a combination of medicines.

Pharmacological Effects of Losartan Potassium.

1. Angiotensin II is the main active substance of the renin-angiotensin system, a potent vasoconstrictor that plays a major role in the pathophysiological process of hypertension.

Angiotensin II binds to AT1 receptors in a variety of tissues (e.g., vascular smooth muscle, adrenal glands, kidney, and heart), producing a variety of important biological effects including vasoconstriction and aldosterone release.

It also stimulates smooth muscle cell proliferation. Another angiotensin II receptor subtype, AT2, has been demonstrated, but its role in the functional homeostasis of the cardiovascular system is unclear.

2. Chlorosartan is a synthetic, potent, orally active drug. The combination of test and pharmacological bioassay proved that it can selectively bind to AT1 receptor.

In vitro and in vivo studies have shown that chlorosartan and its pharmacologically active carboxylic acid metabolite (E-3174) can block the corresponding physiological effects of angiotensin II synthesised from any source or by any route.

Compared with other peptide angiotensin II antagonists, chlorosartan has no agonistic effect.

3, Chlorthalidomide can selectively act on the AT1 receptor, does not affect the function of other hormone receptors or important ion channels in the cardiovascular, and does not inhibit the angiotensin-converting enzyme (kininase II) that degrades bradykinin.

Therefore, effects not directly related to blockade of AT1 receptors such as bradykinin-mediated effects or oedema (1.7% for cloxartan, 1.9% for placebo) are not associated with cloxartan.

Drug interactions of Bulk Losartan Potassium Powder.

1, In clinical pharmacokinetic studies, it has been confirmed that there are no clinically significant drug interactions with hydrochlorothiazide, digoxin, warfarin, cimetidine, phenobarbital, ketoconazole and erythromycin.

2. Rifampicin and fluconazole have been reported to reduce levels of active metabolites. The clinical outcomes of these interactions have not been evaluated.

3, As with other drugs that inhibit angiotensin II and its effects, this product can cause an increase in blood potassium when combined with potassium-preserving diuretics (e.g., spironolactone, aminopterin, amiloride), potassium supplements, or salt substitutes containing potassium.

4, As with other antihypertensive drugs, the nonsteroidal anti-inflammatory drug indomethacin reduces the antihypertensive effect of chlorosartan.